objective To evaluate mother and infant outcomes in the largest prevention of mother-to-childtransmission (PMTCT) programme in Haiti in order to identify gaps towards elimination of HIV and syphilis.
Introduction
There have been tremendous strides towards the elimination of mother-to-child-transmission (MTCT) of HIV and syphilis throughout many low-and middle-income countries (LMICs). The overall number of children newly infected with HIV in LMICs dropped by 35% from 400 000 in 2009 to 160 000 in 2016 [1] . The rate of MTCT of HIV in Latin American and the Caribbean has fallen by 53%, from 15% in 2010 to 8% in 2015, and new infections among children <14 years declined from 10 600 in 2000 to 2100 in 2015 [2, 3] . In September 2010, the Pan American Health Organization (PAHO) advocated for dual elimination of MTCT of HIV and syphilis in the region, defined as <2% infant HIV infection and <0.05 cases of congenital syphilis per 1000 live births [3] .
While several countries in the Caribbean have achieved elimination of vertical transmission as defined by PAHO, Haiti continues to have one of the highest HIV MTCT rates in the region at 4.7% in 2015 [2, [4] [5] [6] . Haiti remains the poorest country in the Western hemisphere and has the largest number of persons living with HIV in the Caribbean [7] [8] [9] [10] . The Haitian fertility rate is 3.0 infants per woman, and maternal mortality is high at 359/100 000 live births [11] [12] [13] . Of an estimated 250 000 infants born each year, approximately 6200 (2.3%) are HIV-exposed [14] . In October 2012, the Haitian Ministry of Health recommended Option B+, lifelong antiretroviral therapy (ART) for HIV+ pregnant women regardless of immune status, with the goal of eliminating MTCT by 2030 [15] .
The objective of this analysis was to report mother and infant HIV and syphilis outcomes across the prevention of mother-to-child-transmission (PMTCT) care continuum at the clinic of the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHES-KIO) from the beginning of the PMTCT programme in 1999 through implementation of Option B+. By identifying where mothers and infants are being lost from PMTCT care, we hope to design interventions to eliminate MTCT in Haiti.
Methods

Study population and setting
Retrospective clinical and laboratory data were abstracted from HIV+ pregnant women who enrolled in the GHESKIO PMTCT programme from January 1999 through December 2014. The non-governmental organisation GHESKIO in downtown Port-au-Prince is the oldest and largest provider of HIV services in the Caribbean, having provided testing since 1985 and treatment since 2003 [16] . GHESKIO is the largest provider of PMTCT services in the country and provides HIV testing to more than 4000 new pregnant women per year, of whom approximately 9% are HIV infected.
PMTCT services
At PMTCT programme entry, HIV+ pregnant women received a physical examination, a CD4+ count, WHO staging, tetanus toxoid vaccination and antenatal assessment. Viral load monitoring was not available until after 2014. Syphilis testing was provided using rapid plasma regain (RPR Becton Dickinson) followed by treponemal confirmation with TPHA in periods 1 and 2. In periods 3 and 4, the screening algorithm included rapid testing with SD Bioline followed by RPR if Bioline was positive. Women who tested positive for syphilis were treated with antibiotics, and all infants were evaluated at birth. The PMTCT guidelines for maternal HIV treatment, breast feeding and infant prophylaxis and testing followed WHO and national guidelines and are described in Table 1 and reported by programmatic period: period 1  (1999-2004 [17] [18] [19] .
Clinic visits were routinely scheduled every month through 18 months after delivery. Each visit included free medication refills (ferrous sulphate, folic acid and antiretroviral medications) and counselling on medication adherence, breast feeding, infant care and family planning. After 18 months, mothers were referred to the adult HIV clinic for ongoing care. HIV-exposed infants were enrolled in the PMTCT clinic and followed until final HIV uninfected status was documented between 12 and 24 months. HIV-infected infants were enrolled on ART and followed further in the GHESKIO paediatric clinic.
Retention in care and adherence to therapy were encouraged by peer counselling, social support programmes and transportation reimbursement of $1-2 per clinic visit. Field workers attempted to find patients who missed a clinic appointment for up to 6 months from the date of the missed appointment to ascertain vital status and re-engage them in care.
Definitions of PMTCT care continuum steps
Mother enrolment in PMTCT services was defined as at least one PMTCT clinic visit. Receipt of maternal antiretroviral (ARV) medications prior to delivery was defined as receipt of mono, dual or triple ARVs prior to or during pregnancy through the date of delivery. Maternal retention through delivery was defined as a clinic visit of the mother after delivery of an infant, excluding women with stillbirths, miscarriages or abortions. GHESKIO does not have delivery facilities and deliveries occurred at home or other facilities. Infant enrolment in PMTCT care was defined as an HIV-exposed infant having at least one clinical visit in the PMTCT programme after the date of delivery. Infant HIV testing was defined as receiving HIV diagnostic tests per Haitian and WHO guidelines prior to 24 months of age as described in Table 1 [20, 21] . Infant HIV testing consisted of early and final HIV status. Early HIV testing was recommended for all infants before 2 months of age using the diagnostic tests described in Table 1 . Infants with an early HIV-negative test received final HIV status defined as a negative PCR or antibody test after breastfeeding cessation or beyond 12 months of age. The rate of MTCT was defined as the proportion of infants who tested HIV-positive among all infants tested. • DNA PCR (ERoche Amplicor HIV-1 DNA PCR) at 4-6 weeks after birth
• If DNA PCR at 4-6 weeks negative, a second PCR was done at 4-6 weeks after completion of breast feeding or beyond 12 months Children >18 months:
• Positive Determine HIV ½ (Abbot) and Capillus HIV1/2 (Trinity Biotec)
• If Determine and Capillus results were discrepant, a Western blot was done for final diagnosis
Clinical measurements
Sociodemographic and clinical measurements of the mother at the time of PMTCT enrolment included sex, age, income, educational level, CD4+ count, WHO Stage and syphilis testing outcome. Infant measurements included weight at PMTCT enrolment and place of delivery. Date of antiretroviral therapy or prophylaxis initiation was defined as the first date that antiretroviral medications were dispensed during pregnancy or the post-partum period. Clinic visits and pharmacy pickup dates were included from date of PMTCT enrolment until the day the study ended (December 1, 2015). Death was ascertained in medical records.
Patient information was documented by healthcare providers in GHESKIO's electronic medical record system. Data quality was assessed quarterly for completeness and accuracy by comparing paper and electronic records.
Statistical analysis
Anonymised data on sociodemographic and clinical variables were extracted from the EMR. The number and proportion of patients achieving each step in the PMTCT continuum were calculated. Retention of mothers in PMTCT care and infants in PMTCT care was assessed from time of enrolment in PMTCT care using KaplanMeier techniques. Lost to follow-up was defined as no clinic or pharmacy visit within 90 days of 12 months after PMTCT enrolment for mothers and within 30 days from 18 months after infant PMCT enrolment for infants. Patients who transferred were censored at the date of transfer. We used STATA statistical software (Version 13.0, College Station, TX, USA) for all analyses.
Ethics
This analysis was approved by the institutional review boards at Weill Cornell Medicine and the Ethics Board at GHESKIO.
Results
Characteristics of HIV-infected pregnant women at PMTCT Enrolment
A total of 3737 women with 4665 unique pregnancies enrolled in PMTCT care at GHESKIO during the study period (Table 2, Figure 1 ). Median age at time of enrolment was 27 years (IQR [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . A third of women were single mothers, and over half earned no income. About 91% lived in Port-au-Prince. The median maternal CD4+ count at time of PMTCT enrolment was 494 cells/ll (IQR 328-691); yet, over half of women were missing a CD4+ count at time of enrolment (CD4 testing not routinely available prior to 2004). About 16% of pregnant women had advanced WHO Stage III/IV, and 8% had a diagnosis of syphilis at the time of enrolment in care; • DNA PCR (ERoche Amplicor HIV-1 DNA PCR) at 4-6 weeks after birth
• If DNA PCR at 6 weeks negative, a second PCR was done at 4-6 weeks after completion of breast feeding or beyond 12 months Children >18 months:
• If Determine and Capillus results were discrepant, a Western blot was done for final diagnosis PMTCT, ART initiation, and Infant HIV testing and diagnosis followed WHO and Haitian national guidelines.
however, 18% lacked documentation of a syphilis test (Table 2) .
PMTCT care continuum
In 75% of the 4665 unique pregnancies, pregnant women received either ARV prophylaxis (33%) or ART (42%). Among the 1942 women who received ART, 790 (41%) were on ART prior to presentation to PMTCT care, 485 (25%) started the same day as PMTCT enrolment, and 667 (34%) started after day of PMTCT enrolment but during pregnancy. Receipt of ARV prophylaxis or ART during pregnancy increased from 64% (424/666) in period 1 to 92% (816/883) in period 4 ( Figure 2 ). Among women who received any ARV or ART during pregnancy, the proportion who received ART increased from 6% (24/424) in period 1 to 100% (816/816) in period 4 ( Figure 3 ). Median time from PMTCT enrolment to ARV or ART start for pregnant women decreased from 64 days (IQR 20-111) in period 1 to 0 days (IQR 0-0) in period 4. About 73% (3414/4665) of all HIV+ pregnant women were retained in PMTCT care through delivery of a live infant (Figure 2) . A total of 1004 women were lost from PMTCT care prior to delivery; there were 296 stillbirths, miscarriages or abortions, and 11 maternal deaths (Figure 1 ). Retention of women in PMTCT care through the delivery of an infant increased from 68% (454/666) in period 1 to 74% (657/883) in period 4 (P = 0.042 test for trend) but remained the step at which the most women were lost across all periods. About 18% (178) of the 1004 women who were before delivery only attended one PMTCT visit; their rate increased from 8.5% (16/188) in period 1 to 23% (40/171) in period 4.
About 94% of the infants of the 3414 mothers retained in PMTCT care through delivery were enrolled in PMTCT care; this rate was consistently high across all periods ( Figure 2 ). About 74% received neonatal prophylaxis with AZT. About 50% were girls and median infant weight at time of PMCT enrolment was 4.52 kg (IQR 3.36-5.35 kg). Breastfeeding guidelines evolved over periods, with breastfeeding being contraindicated in periods 1 and 2 and being recommended with maternal ART in periods 3 and 4. Accordingly, rates of reported breastfeeding increased from 3% of women reporting exclusive breastfeeding in period 1-2 to 26% in period 3 and 40% in period 4. About 92% (2955/3218) of infants enrolled in PMTCT care were tested for HIV (Figure 2 ). Seventy-six died before testing, 20 had incomplete tests and 166 were lost to care (Figure 1 ). The proportion of HIV-exposed infants tested for HIV was consistently high across all programme periods: 83%, 93%, 95% and 90% in periods 1-4, respectively (Figure 2) .
A total of 161 (5.4%) infants were diagnosed to be HIV-infected per the infant HIV testing algorithm described in Table 1 . The rate of MTCT ranged from 9.9% (37/375) in period 1 to 4.6% (52/1134) in period 2, 5.9% (52/885) in period 3 and 3.6% (20/560) in period 4 ( Figure 2 ). Figure 3 reports the rate of HIV MTCT by calendar year. MTCT increased from 4.2% (15/359) in 2009 to 8.5% (23/271) in 2010 (P = 0.0005), the year of the earthquake in Haiti. Twelve months after birth 44% of the 161 HIV-infected infants were alive in care, 23% had died and 32% were lost to care. In a sensitivity analysis assuming an HIV transmission rate of 10% among the 459 infants who died or were lost prior to HIV testing, the overall MTCT would increase to 6.0%. Assuming 20% and 30% HIV transmission rates, the overall rate of MTCT would further increase to 7.4% and 8.7%, respectively. By programme period, and assuming 10% and 30% HIV transmission rates, the rate of MTCT would be 10-13% in period 1, 5-8% in period 2, 6-9% in period 3 and 5-7% in period 4.
Median time of follow-up for women in each of these pregnancies was 15.9 months (IQR 7.4-21.2) and for the 3218 infants who enrolled in PMTCT care, median time of follow-up was 19.8 months (IQR 8.0-24.6). Retention of mothers from time of PMTCT enrolment through 12 months was 82% (95% CI 0.81-0.84) and did not significantly differ across programme periods (log rank Pvalue = 0.75) (Figure 4) . The largest drop occurred in the first 3 months of PMTCT care, which corresponds with the time near their expected delivery. The proportion of women who were lost prior to delivery ranged from 32% in period 1 to 26% in period 4 ( Figure 2 ). Retention at 12 months after delivery was 70.5% (95% CI 66.2-74.4), in period 1, 72.0% (95% CI 69.6-74.3%) in period 2, 72.8% (95% CI 69.9-75.4%) in period 3 and 53.7% (95% CI 50.2-57.0) in period 4 (log rank P-value < 0.0001).
Retention of women who received ARV or ART vs. those who did not was higher across all programme periods (Table S1 ). We also compared retention among pregnant women who received ART at time of PMTCT enrolment excluding those who were on ART prior to PMTCT enrolment ( Figure 5 ) to determine whether women who received ART under Option B+ (period 4) differed from women who started ART during PMTCT in earlier periods. A total of 1286 women received ART at time of PMTCT enrolment across periods 2-4 (no women received ART at time of PMTCT enrolment in period 1, a total of 140 women in period 2, 397 women in period 3 and 749 in period 4). Retention at one year among these Across all periods, 77% (95% CI 0.75-0.78) and 76% (95% CI 0.75-0.78) of infants were retained at 12 months after PMTCT enrolment, respectively. There was no difference across programme periods in infant retention (log rank P-value 0.24) (Figure 6 ).
Syphilis testing across periods
The proportion of women who tested positive for syphilis fell from 16% (95/601) in period 1 to 8% (62/760) in period 4 (Table 1) , whereas syphilis testing of infants rose from 17% to 91% across period 1-4, with 2 of 1682 infants being positive across all periods.
Discussion
This study documents the progress made and ongoing challenges towards eliminating MTCT of HIV and syphilis over the past 15 years at the largest PMTCT clinic in Haiti. HIV transmission decreased from a peak of 13.2% in 2003 to 4.1% in 2014 with the expansion of ART through Option B+. Syphilis diagnoses among HIVinfected pregnant women also decreased over time in the period of Option B+. Despite these improvements, Haiti has fallen short of the PAHO elimination goal of MTCT, due in part to HIV-infected mothers being lost across the HIV care continuum, as seen in other resource-poor settings [22, 23] . This study identified two potential targets for future efforts to retain mothers in PMTCT care: first, the greatest attrition of HIV-infected pregnant women occurred prior to mothers returning with their infants after delivery, which was the only step in the continuum with retention <90%. Second, fewer women who received ART at enrolment in PMTCT care were retained in the era of Option B+ compared to similar women in earlier periods. This study is unique in that it includes programmatic data spanning the entire history of Haiti's largest PMTCT programme beginning in 1999 through implementation of Option B+ and builds upon previous interim analyses [14, 24, 25] . Before ART could be accessed in Haiti, the rate of MTCT was 27% [14, 26] . This MTCT rate is similar to a rural PMTCT programme in Haiti in the same time period [27] . Slightly higher rates in era of Option B+ may be due to greater attrition of HIV+ mothers who started ART at time of PMTCT enrolment as compared to prior periods.
Rates of MTCT in the era of Option B+ in this study appear similar to other resource-limited settings. For example, in Malawi which was one of the first countries to nationally implement Option B+, MTCT decreased from 27% in 2009 to 9% in 2015, with 80% of HIVpositive mothers on ART [28] . South Africa, Uganda, Swaziland and Namibia have achieved rates below 5% as of 2015 [29] . Unfortunately, MTCT surged after the 2010 earthquake, as the country's health infrastructure weakened and women were displaced from health facilities -many moved to rural areas for home security and assistance from families [30] . This underscores the vulnerability of HIV+ pregnant women and their infants when the health infrastructure is disrupted by conflict and natural disasters.
Our reported HIV transmission rates may be underestimated given we only report ascertained HIV infection among HIV-exposed infants who were retained long enough to complete HIV testing. We lack outcomes for infants who were lost to follow-up or died prior to testing. Moreover, infant deaths are ascertained only by selfreport from the family.
To achieve elimination of MTCT, retention across all steps of the PMTCT continuum is essential [31] . In this analysis, infant retention through 18 months is much higher than in other studies evaluating HIV programmes in resource poor countries [32, 33] . At 3 months after infant enrolment in PMTCT at GHESKIO, only 15% of infants were lost vs. 34% in a meta-analysis of 14 studies from resource-poor countries [32] . Attrition (26%) was greatest around the time of delivery, as has been reported as a challenge in other studies [34] [35] [36] . A PMTCT clinic in Les Cayes, Haiti reported 20% of women becoming lost by time of delivery [25, 35] . The most common reason cited was moving for delivery to another town, often due to the lack of financial resources for facility-based delivery and the need for family support. Our previous analysis also found that women who were on ARV or ART during pregnancy were more likely to be retained in care after delivery [24] . Unfortunately, Haiti does not have a unique national identification number to track patients across clinics that would enable us to measure transfers [37] .
Our finding of suboptimal retention of mothers in the era of Option B+ is a challenge and has been reported in other settings [25, 35, [38] [39] [40] [41] . A retrospective study in Haiti among adults who initiated ART between 2012 through 2014 found that attrition among pregnant women who received ART under Option B+ was 50.4% (95% CI 48.6-52.3%) at 12 months after ART initiation [35] . Another study of 2166 HIV+ pregnant women at 68 HIV clinics in Haiti receiving Option B+ reported that 47.2% were not retained at 12 months after PMTCT enrolment [34] . A national study of Malawi's Option B+ programme of 21 939 HIV+ pregnant women reported 17% lost at 6 months after ART start [38] . Women who started ART under Option B+ were five times more likely to be lost than women who started ART for their own health (i.e. advanced WHO stage or CD4+ count <350 cells/ll) with OR 5.0 (95% CI 4.2-6.1). The Safe Generations Study in Swaziland similarly reported that the postnatal retention rate among women on ART was lower under Option B+ than earlier PMTCT regimens (53% vs. 65%, P < 0.001) [42] .
Reasons for attrition across the PMTCT continuum, regardless of PMTCT regimen, are multifactorial and include individual, clinic and community factors [43] [44] [45] . Individual-level factors are little knowledge of HIV and MTCT, psychological distress and perceived stigma. Community-level factors are partner and family support, cultural traditions, disclosure, transport and child care costs, and extended travel to a rural home for delivery [46] . Clinic-level factors comprise long waiting times, inconvenient hours and perceived negative staff attitudes [47] . Other barriers in the era of Option B+ may be overburdened PMTCT programmes as a result of expanded ART eligibility, lack of adequate advance counselling or rushed ART initiation of apparently healthy mothers, and lack of motivation to adhere to lifelong medication after a healthy delivery [47, 48] . In Malawi initiation of ART in HIV+ pregnant women on the same day as HIV diagnosis vs. several days later was associated with a lower retention rate in the first 6 months (adjusted odds ratio 2.27, 95% CI 1.34-3.85) [49] .
Proposed interventions to improve retention around the time of delivery include formalisation or improvement of the transfer of PMTCT care to follow women who need to return to rural areas for delivery [45] . Other options include peer support models and financial assistance for women to deliver in health facilities to eliminate the need to migrate to rural areas [50] .
A strength of this analysis is that it reports outcomes from the largest PMTCT programme in Haiti and compares them across its entire history from the time before widespread availability of ART to the era of Option B+. Limitations are (i) that the data are from one PMTCT facility, which limits their generalisability; (ii) that outcomes of lost mothers and infants are unknown; and (iii) that our definitions of retention in care may differ from those of other studies [51] .
Conclusion
In summary, Haiti has made impressive strides in the reduction of mother-to-child transmission of HIV and syphilis. This study reports 15 years of results from a comprehensive PMTCT programme beginning with monotherapy through Option B+. Remarkably, at all steps in the PMTCT continuum except the time of delivery 90% of mothers were in care. Interventions are urgently needed to improve retention at time of delivery if Haiti is to achieve elimination of MTCT HIV and syphilis.
